COSMO PHARMACEUTICALS NV (C43.DE) Fundamental Analysis & Valuation

FRA:C43 • NL0011832936

48.8 EUR
-1.2 (-2.4%)
Last: Apr 29, 2025, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This C43.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

8

C43 gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 54 industry peers in the Pharmaceuticals industry. C43 scores excellent points on both the profitability and health parts. This is a solid base for a good stock. An interesting combination arises when we look at growth and value: C43 is growing strongly while it also seems undervalued. C43 also has an excellent dividend rating. These ratings could make C43 a good candidate for value and dividend and growth and quality investing.


Dividend Valuation Growth Profitability Health

8

1. C43.DE Profitability Analysis

1.1 Basic Checks

  • C43 had positive earnings in the past year.
  • In the past year C43 had a positive cash flow from operations.
  • In multiple years C43 reported negative net income over the last 5 years.
  • Each year in the past 5 years C43 had a positive operating cash flow.
C43.DE Yearly Net Income VS EBIT VS OCF VS FCFC43.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 20.60%, C43 belongs to the top of the industry, outperforming 94.23% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 26.74%, C43 is in the better half of the industry, outperforming 76.92% of the companies in the same industry.
  • C43 has a better Return On Invested Capital (21.60%) than 88.46% of its industry peers.
Industry RankSector Rank
ROA 20.6%
ROE 26.74%
ROIC 21.6%
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
C43.DE Yearly ROA, ROE, ROICC43.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20

1.3 Margins

  • C43's Profit Margin of 49.94% is amongst the best of the industry. C43 outperforms 98.08% of its industry peers.
  • C43's Profit Margin has improved in the last couple of years.
  • With an excellent Operating Margin value of 55.81%, C43 belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • C43's Operating Margin has improved in the last couple of years.
  • The Gross Margin of C43 (83.00%) is better than 86.54% of its industry peers.
  • In the last couple of years the Gross Margin of C43 has grown nicely.
Industry RankSector Rank
OM 55.81%
PM (TTM) 49.94%
GM 83%
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
C43.DE Yearly Profit, Operating, Gross MarginsC43.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. C43.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so C43 is creating value.
  • C43 has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for C43 has been increased compared to 5 years ago.
  • The debt/assets ratio for C43 has been reduced compared to a year ago.
C43.DE Yearly Shares OutstandingC43.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
C43.DE Yearly Total Debt VS Total AssetsC43.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • C43 has an Altman-Z score of 5.80. This indicates that C43 is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of C43 (5.80) is better than 90.38% of its industry peers.
  • The Debt to FCF ratio of C43 is 0.01, which is an excellent value as it means it would take C43, only 0.01 years of fcf income to pay off all of its debts.
  • C43 has a better Debt to FCF ratio (0.01) than 98.08% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that C43 is not too dependend on debt financing.
  • The Debt to Equity ratio of C43 (0.00) is better than 94.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.01
Altman-Z 5.8
ROIC/WACC2.81
WACC7.68%
C43.DE Yearly LT Debt VS Equity VS FCFC43.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

  • C43 has a Current Ratio of 4.19. This indicates that C43 is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 4.19, C43 belongs to the best of the industry, outperforming 96.15% of the companies in the same industry.
  • C43 has a Quick Ratio of 3.91. This indicates that C43 is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.91, C43 belongs to the top of the industry, outperforming 96.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.19
Quick Ratio 3.91
C43.DE Yearly Current Assets VS Current LiabilitesC43.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

9

3. C43.DE Growth Analysis

3.1 Past

  • C43 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1315.29%, which is quite impressive.
  • Measured over the past years, C43 shows a very strong growth in Earnings Per Share. The EPS has been growing by 85.20% on average per year.
  • Looking at the last year, C43 shows a very strong growth in Revenue. The Revenue has grown by 187.55%.
  • The Revenue has been growing by 33.68% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%

3.2 Future

  • C43 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.02% yearly.
  • C43 is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.67% yearly.
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
C43.DE Yearly Revenue VS EstimatesC43.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
C43.DE Yearly EPS VS EstimatesC43.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20

More info and screens

Find the best growth stocksShow best growing peers

8

4. C43.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 5.98, which indicates a rather cheap valuation of C43.
  • Compared to the rest of the industry, the Price/Earnings ratio of C43 indicates a rather cheap valuation: C43 is cheaper than 92.31% of the companies listed in the same industry.
  • C43's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.71.
  • With a Price/Forward Earnings ratio of 8.09, the valuation of C43 can be described as very reasonable.
  • 84.62% of the companies in the same industry are more expensive than C43, based on the Price/Forward Earnings ratio.
  • C43's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.82.
Industry RankSector Rank
PE 5.98
Fwd PE 8.09
C43.DE Price Earnings VS Forward Price EarningsC43.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of C43 indicates a rather cheap valuation: C43 is cheaper than 96.15% of the companies listed in the same industry.
  • 94.23% of the companies in the same industry are more expensive than C43, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 5.46
EV/EBITDA 3.83
C43.DE Per share dataC43.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

  • C43 has an outstanding profitability rating, which may justify a higher PE ratio.
  • C43's earnings are expected to decrease with -27.68% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. C43.DE Dividend Analysis

5.1 Amount

  • C43 has a Yearly Dividend Yield of 3.85%.
  • In the last 3 months the price of C43 has falen by -28.24%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
  • Compared to an average industry Dividend Yield of 1.91, C43 pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.82, C43 pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.85%

5.2 History

  • The dividend of C43 is nicely growing with an annual growth rate of 7.41%!
Dividend Growth(5Y)7.41%
Div Incr Years1
Div Non Decr Years1
C43.DE Yearly Dividends per shareC43.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 1 2 3 4

5.3 Sustainability

  • 24.09% of the earnings are spent on dividend by C43. This is a low number and sustainable payout ratio.
  • C43's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP24.09%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
C43.DE Yearly Income VS Free CF VS DividendC43.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M
C43.DE Dividend Payout.C43.DE Dividend Payout, showing the Payout Ratio.C43.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

C43.DE Fundamentals: All Metrics, Ratios and Statistics

COSMO PHARMACEUTICALS NV

FRA:C43 (4/29/2025, 7:00:00 PM)

48.8

-1.2 (-2.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-06
Earnings (Next)07-23
Inst Owners12.98%
Inst Owner ChangeN/A
Ins Owners38.78%
Ins Owner ChangeN/A
Market Cap855.95M
Revenue(TTM)266.79M
Net Income(TTM)133.24M
Analysts84
Price Target104.72 (114.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.85%
Yearly Dividend2
Dividend Growth(5Y)7.41%
DP24.09%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)2.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-13.87%
Revenue NY rev (3m)-12.84%
Valuation
Industry RankSector Rank
PE 5.98
Fwd PE 8.09
P/S 3.21
P/FCF 5.46
P/OCF 5.27
P/B 1.72
P/tB 6.01
EV/EBITDA 3.83
EPS(TTM)8.16
EY16.72%
EPS(NY)6.03
Fwd EY12.36%
FCF(TTM)8.94
FCFY18.31%
OCF(TTM)9.26
OCFY18.97%
SpS15.21
BVpS28.41
TBVpS8.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 20.6%
ROE 26.74%
ROCE 24.88%
ROIC 21.6%
ROICexc 28.38%
ROICexgc 129.8%
OM 55.81%
PM (TTM) 49.94%
GM 83%
FCFM 58.76%
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y181.33%
ROICexgc growth 5YN/A
ROICexc growth 3Y154.84%
ROICexc growth 5YN/A
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
F-Score8
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.01
Debt/EBITDA 0.01
Cap/Depr 46.02%
Cap/Sales 2.12%
Interest Coverage 250
Cash Conversion 100.77%
Profit Quality 117.65%
Current Ratio 4.19
Quick Ratio 3.91
Altman-Z 5.8
F-Score8
WACC7.68%
ROIC/WACC2.81
Cap/Depr(3y)45.29%
Cap/Depr(5y)77.05%
Cap/Sales(3y)4.67%
Cap/Sales(5y)8.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
EBIT growth 1Y8040.37%
EBIT growth 3Y137.59%
EBIT growth 5YN/A
EBIT Next Year-33.52%
EBIT Next 3Y-14.79%
EBIT Next 5Y28.59%
FCF growth 1Y756.04%
FCF growth 3Y236.69%
FCF growth 5YN/A
OCF growth 1Y615.22%
OCF growth 3Y134.4%
OCF growth 5YN/A

COSMO PHARMACEUTICALS NV / C43.DE FAQ

What is the fundamental rating for C43 stock?

ChartMill assigns a fundamental rating of 9 / 10 to C43.DE.


What is the valuation status for C43 stock?

ChartMill assigns a valuation rating of 8 / 10 to COSMO PHARMACEUTICALS NV (C43.DE). This can be considered as Undervalued.


What is the profitability of C43 stock?

COSMO PHARMACEUTICALS NV (C43.DE) has a profitability rating of 8 / 10.


Can you provide the expected EPS growth for C43 stock?

The Earnings per Share (EPS) of COSMO PHARMACEUTICALS NV (C43.DE) is expected to decline by -23.67% in the next year.


How sustainable is the dividend of COSMO PHARMACEUTICALS NV (C43.DE) stock?

The dividend rating of COSMO PHARMACEUTICALS NV (C43.DE) is 8 / 10 and the dividend payout ratio is 24.09%.